Medigen Biotechnology (3176) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigen Biotechnology (3176) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-18.91 Million ≈ $-595.86K USD) by net assets (NT$4.90 Billion ≈ $154.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Medigen Biotechnology's balance sheet to measure how much of total assets are equity-financed.
Medigen Biotechnology - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medigen Biotechnology (3176) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Medigen Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Long Teng Development Co Ltd
TWO:3188
|
-0.079x |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
0.029x |
|
Kross Ltd
NSE:KROSS
|
0.010x |
|
Bassett Furniture Industries
NASDAQ:BSET
|
-0.145x |
|
Tenaya Therapeutics Inc
NASDAQ:TNYA
|
-0.188x |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
0.019x |
|
Malaysia Marine and Heavy Engineering Holdings Bhd
KLSE:5186
|
-0.037x |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
0.000x |
Annual Cash Flow Conversion Efficiency for Medigen Biotechnology (2003–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Medigen Biotechnology.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.04 Billion ≈ $158.73 Million |
NT$37.92 Million ≈ $1.19 Million |
0.008x | +106.61% |
| 2023-12-31 | NT$5.00 Billion ≈ $157.44 Million |
NT$-569.40 Million ≈ $-17.94 Million |
-0.114x | +34.61% |
| 2022-12-31 | NT$6.47 Billion ≈ $203.87 Million |
NT$-1.13 Billion ≈ $-35.53 Million |
-0.174x | -316.41% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.46 Million |
NT$517.45 Million ≈ $16.30 Million |
0.081x | +153.97% |
| 2020-12-31 | NT$4.50 Billion ≈ $141.76 Million |
NT$-671.38 Million ≈ $-21.15 Million |
-0.149x | +28.47% |
| 2019-12-31 | NT$2.69 Billion ≈ $84.60 Million |
NT$-560.17 Million ≈ $-17.65 Million |
-0.209x | -15.80% |
| 2018-12-31 | NT$2.94 Billion ≈ $92.66 Million |
NT$-529.82 Million ≈ $-16.69 Million |
-0.180x | -25.74% |
| 2017-12-31 | NT$3.18 Billion ≈ $100.19 Million |
NT$-455.62 Million ≈ $-14.35 Million |
-0.143x | -8.16% |
| 2016-12-31 | NT$3.54 Billion ≈ $111.46 Million |
NT$-468.61 Million ≈ $-14.76 Million |
-0.132x | -255.98% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.14 Million |
NT$294.18 Million ≈ $9.27 Million |
0.085x | -31.58% |
| 2005-12-31 | NT$650.39 Million ≈ $20.49 Million |
NT$80.72 Million ≈ $2.54 Million |
0.124x | -76.13% |
| 2003-12-31 | NT$856.65 Million ≈ $26.99 Million |
NT$445.46 Million ≈ $14.03 Million |
0.520x | -- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more